- AstraZeneca’s Core Earnings Per Share (EPS) for the second quarter of 2025 was $2.17, matching analysts’ estimates.
- The company’s core operating profit reached $4.58 billion, slightly surpassing the estimated $4.5 billion.
- Core gross profit totaled $11.91 billion, exceeding the anticipated $11.76 billion, while the core gross margin was recorded at 82%, just shy of the 82.3% expectation.
- Collaboration revenue fell significantly short of expectations, bringing in $8 million compared to an estimated $45.8 million.
- Alliance revenue outperformed estimates, generating $654 million against the forecasted $640.9 million.
- Product sales were strong, totaling $13.80 billion compared to the $13.44 billion estimate.
- Key pharmaceutical products showed varying results: Tagrisso earned $1.81 billion, Lynparza $838 million, Calquence $872 million, and Imfinzi $1.46 billion, all meeting or exceeding expectations.
- Fasenra and Farxiga revenues were particularly robust, with respective earnings of $502 million and $2.15 billion, both surpassing estimates.
- Nexium and Crestor revenues reached $201 million and $320 million, with Crestor surpassing the expected $299.2 million.
- Brilinta’s revenue fell short of projections, achieving $215 million versus an estimated $252.1 million.
- Symbicort, Ultomiris, and Soliris revenues all exceeded their forecasts, contributing positively to overall sales.
- Strensiq and Saphnelo revenues were above estimates, while Breztri revenue underperformed, bringing in $283 million compared to the expected $301.1 million.
- AstraZeneca anticipates that full-year 2025 Total Revenue and Core EPS growth will be broadly similar to growth at constant exchange rates (CER), given stable foreign exchange rates.
- The company’s financial guidance for the full year 2025 remains unchanged, based on the average foreign exchange rates through 2024.
- Market sentiment is largely positive with 26 buy ratings, 5 hold ratings, and no sell ratings as reported by analysts.
A look at AstraZeneca PLC Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 5 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
AstraZeneca PLC, as indicated by its Smart Scores, shows a promising long-term outlook in various key factors. With a strong emphasis on growth, the company scores a high 5 in this aspect, indicating positive potential for expansion and development. Additionally, AstraZeneca also demonstrates steady momentum and resilience with scores of 3 in both categories, showcasing its ability to adapt to changing market conditions and maintain a consistent performance. While value and dividend scores are slightly lower, at 2 and 3 respectively, the company’s focus on innovation and growth positions it well for future success.
Operating as a holding company, AstraZeneca PLC is engaged in researching, manufacturing, and selling pharmaceutical and medical products through its subsidiaries. The company’s primary focus lies in eight therapeutic areas, including gastrointestinal, oncology, cardiovascular, respiratory, central nervous system, pain control, anaesthesia, and infection. With a strong emphasis on growth and a resilient operational framework, AstraZeneca is poised to navigate challenges and capitalize on opportunities in the pharmaceutical industry moving forward.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
